Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer - A national survey performed at pathology departments in Sweden

Author： Ryden Lisa   Haglund Monica   Bendahl Par-Ola   Hatschek Thomas   Kolaric Aleksandra   Kovacs Aniko   Olsson Ann   Olsson Hans   Strand Carina   Ferno Mårten  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.48, Iss.6, 2009-08, pp. : 860-866

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer

By Aurilio Gaetano   Monfardini Lorenzo   Rizzo Stefania   Sciandivasci Angela   Preda Lorenzo   Bagnardi Vincenzo   Disalvatore Davide   Pruneri Giancarlo   Munzone Elisabetta   Della Vigna Paolo   Renne Giuseppe   Bellomi Massimo   Curigliano Giuseppe   Goldhirsch Aron   Nolè Franco  

Acta Oncologica, Vol. 52, Iss. 8, 2013-11 ,pp. : 1649-1656

Informa Healthcare

Access to resources Recommend Favorite

Human epidermal growth factor receptor 2 protein expression between primary breast cancer and paired asynchronous local-regional recurrences

By                

Experimental and Therapeutic Medicine, Vol. 2, Iss. 6, 2011-01 ,pp. : 1187-1191

Spandidos Publications

Access to resources Recommend Favorite

Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies

By Blank Patricia  

Breast Cancer Research and Treatment, Vol. 124, Iss. 2, 2010-11 ,pp. : 497-507

Springer Publishing Company

Access to resources Recommend Favorite

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer

By Alvarez Ricardo  

Breast Cancer, Vol. 20, Iss. 2, 2013-04 ,pp. : 103-110

Springer Publishing Company

Access to resources Recommend Favorite

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

By Hayashi Naoki  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 523-531

Springer Publishing Company

Access to resources Recommend Favorite